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omCerebral venous sinus (sinovenous) thrombosis
(CSVT) is an increasingly recognized cause of
childhood and neonatal stroke. Recent develop-
ments in the field highlight the expanding spec-
trum of perinatal brain injury associated with
neonatal CSVT. Although there is considerable
overlap in risk factors for neonatal and childhood
CSVT, specific differences exist between the
groups. Management remains controversial,
unlike in adult sinovenous thrombosis. However,
morbidity and mortality are significant, highlighting
the continued need for high-quality studies within
this field. This article reviews the literature on child-
hood CSVT (Table 1) and highlights developments
in our understanding of neonatal CSVT.
EPIDEMIOLOGY
More than 40% of childhood CSVT occurs within
the neonatal period, with an incidence of 2.6 per
100,000 children per year in one series.5 The inci-
dence of childhood CSVT varies between 0.4 and
0.7 per 100,000 children per year.12,14 These
figures are probably underestimates of the true
incidence for several reasons. Children with
CSVT, particularly neonates, often present with
nonfocal neurologic signs and symptoms, and
the diagnosis may not be suspected.12 Old
imaging techniques, the variable anatomy of sino-
venous channels and rapid recanalization are alla The Hospital For Sick Children, 555 University Avenue,
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The lack of evidence supporting treatment and
anxieties about safety of anticoagulation may
also have reduced the impetus to make a diag-
nosis, particularly in suspected CSVT associated
with hemorrhage.ANATOMY AND PHYSIOLOGY
OF THE VENOUS SYSTEM IN NEONATES
AND CHILDREN
The venous sinuses and veins lie within the
subarachnoid space. Arachnoid villi project into
the venous sinuses of the dura and are concen-
trated on the superior sagittal sinus, which is
important for absorption and drainage of cerebro-
spinal fluid. Venous drainage is achieved by 2
systems: the superficial and the deep. The super-
ficial drainage system is composed of the superfi-
cial cortical veins, superior sagittal sinus (SSS),
torcula or confluence of veins, right transverse
sinus (dominant in the majority of individuals),
sigmoid sinus, and internal jugular vein. The deep
venous system consists of the basal veins, which
drain blood from the basal ganglia and germinal
matrix in preterm neonates, the Galenic system
with the 2 internal cerebral veins that form the
vein of Galen, the straight sinus, the basal vein of
Rosenthal, the torcula, and the typicallyToronto, ON M5G 1X8, Canada
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Table 1
Pediatric CSVT literature summary
Study
No. of
patients
Demographics, N (%) Risk Factors Infarction (%) Treatment (%) Outcome (%)
Country Males Neonate
None,
N (%) Systemic (N or %) Infection (%) PT (%) Acute ACT Chronic ACT
Follow-up
(y) Death Abnormal
Mallick et al,
20091
21 UK 10 (48) 0 2 (10) Nephrotic
syndrome (3)
Any infection (71) 25 14 100 67 0.42–6 10 29
CNS tumor (1) OM/Mastoiditis (62) Bland (100) UFH (100) Coumadin (100)
OCP (2) Sepsis (10) Hemorrhagic
(0)
LMWH (14) LMWH (19)
Dehydration (14)
Anemia (19)
Vieira et al,
20092
53 Portugal 30 (57) 6 (11) 7 (13) Nephrotic
syndrome (2)
Any infection (57) 40 NR 68 100 1.1–6 0 43
CNS tumor (1) Mastoiditis (43) Coumadin (100)
SLE (1) Meningitis (13)
Head trauma (1)
Diabetes (1)
Chemotherapy (5)
Dehydration (4)
Wasay et al,
20083
70 USA 28 (40) 25 (36) 7 (10) Nephrotic
syndrome (1)
Any infection (40) 56 NR 21 12 NR 13 46
SLE (2) OM/MA/Sinusitis
(24)
Coumadin (100)
SCD (1) Meningitis (3)
Homocystinuria
(3)
Sepsis (13)
Leukemia (2)
OCP (1)
Chemotherapy (1)
Dehydration (4)
Anemia (10)
Fever (33)
Kenet et al,
20074
396 Germany 236 (60) 75 (19) NR NR NR NR 10 63 42 0–7.1 3 NR
Israel Bland (10) UFH (51) LMWH (76)
UK Hemorrhagic
(90)
LMWH (48)
Belgium
Fitzgerald
et al,
20065
42 USA 24 (57) 42 (100) NR Cardiac condition
(11)
Any infection (17) 64 60 7 0 0.2–15 3 79
Dehydration (26) Meningitis (10) Bland (12)
Sepsis (7) Hemorrhagic
(88)
IVH (20)
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Bonduel
et al,
20066
38 Argentina 27 (71) NR 3 (8) SLE (1) Any Infection (50) NR NR 68 68 0.25–11.5 23 32
CNS tumor (2) LMWH (68) Coumadin (100)
Leukemia (8)
Lymphoma (2)
Head trauma (2)
Chemotherapy (7)
Dehydration (5)
Se´bire et al,
20057
42 UK 27 (64) NR 0 Cardiac condition
(2)
Any infection (55) 62 60 43 43 0.5–10 12 62
IBD (1) OM (41) Bland (52) UFH (83)
Nephrotic
syndrome (3)
MA (26) Hemorrhagic
(48)
LMWH (17)
SLE (2)
SCD (2)
Thalassemia (1)
CNS tumor (2)
Leukemia (2)
Dehydration (19)
Anemia (19)
Kenet et al,
20048
46 Israel 29 (63) 8 (17) 7 (15) Cardiac
condition (4)
Any infection (39) 42 NR 88 NR NR 4 17
IBD (1) MA/Sinusitis (35)
SLE (2)
Homocystinuria (1)
OCP (1)
Head trauma (4)
Barnes et al,
20049
16 Australia 8 (50) 0 NR NR Any infection (88) 31 NR 63 NR 0.02–5 NR 38
OM/MA (44) UFH (30)
Meningitis/Abscess
(44)
LMWH (80)
Coumadin (30)
Heller et al,
20035
149 Germany 84 (56) 40 (27) 44 (30) IBD (1) Any infection (44) 56 NR 88 73 NR 0 NR
Nephrotic
syndrome (1)
OM (3) UFH (47) LMWH (100)
Steroid use (3) MA (9) LMWH (40)
OCP (4) Meningitis (4)
Head trauma (10) Sepsis (5)
Sinusitis (3)
Varicella (1)
Gastroenteritis (3)
Wu et al,
200210
30 USA NR 30 (100) 4 (13) Cardiac condition
(7)
Any infection (13) 57 NR NR NR NR NR NR
Dehydration (3) Sepsis (10)
Pneumonia (3)
(continued on next page)
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Table 1
(continued)
Study
No. of
patients
Demographics, N (%) Risk Factors Infarction (%) Treatment (%) Outcome (%)
Country Males Neonate
None,
N (%) Systemic (N or %) Infection (%) PT (%) Acute ACT Chronic ACT
Follow-up
(y) Death Abnormal
Huisman
et al,
200111
19 Switzerland 9 (47) 0 NR Head trauma (9) Any infection (37) NR 11 NR NR NR 11 NR
MA (32)
Meningitis (5)
DeVeber
et al,
200112
160 Canada 87 (57) 69 (43) 4 (3) Cardiac condition (8) Any infection (27) 24 41 53 NR 0.05–5.2 8 38
Dehydration (25) Sepsis (18) Bland (32) LWMH (59)
Hemorrhagic
(68)
UFH (41)
Coumadin (46)
Carvalho
et al,
200013
31 USA 21 (68) 19 (61) NR Cardiac condition (4) Any infection (39) NR 48 0 0 NR 13 52
CNS tumor (1) MA (23)
Chemotherapy (1) Meningitis (10)
Dehydration (13) Sepsis (7)
All studies with more than 10 patients published since 2000 are included.
Abbreviations: ACT, anticoagulation; APTT, activated partial thromboplastin time; CNS, central nervous system; IBD, inflammatory bowel disease; IVH, intraventricular hemorrhage; LMWH,
low molecular weight heparin; MA, mastoiditis; NR, not reported; OCP, oral contraceptive use; OM, otitis media; PT, prothrombotic tendency; SCD, sickle cell disease; SLE, systemic lupus er-
ythematosus; UFH, unfractionated heparin.
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Cerebral Venous Sinus Thrombosis in Children 515nondominant left transverse sinus, which drains
into the left sigmoid sinus and the left internal
jugular vein.
The major venous outflow tracts include the
internal jugular veins (IJV) and extrajugular collat-
eral venous pathways such as the venous verte-
bral plexus and the extracranial emissary veins.
In the supine position assumed by neonates, the
IJV is the major venous outflow tract. However,
in adult studies have shown that, in standing, the
venous vertebral plexus is the main outflow tract.
The extracranial emissary veins, are small, few,
and not thought to play a major role in normal
venous drainage. However, in certain conditions
where there is congenital chronic venous outflow
obstruction, such as craniosynostosis, they
assume a central role providing an extracranial
outflow pathway.15,16 In most infants, the
cavernous sinus is not yet connected to the cere-
bral veins, resulting in less reserve and increased
vulnerability within the venous drainage
system.15,17
Positioning of the neonate has been shown to
have a major influence on venous outflow. Neck
flexion and compression of the SSS by the occip-
ital bone have been implicated in the etiology of
venous stasis and thrombosis,18–20 and is an
area requiring further study.21PATHOPHYSIOLOGICAL MECHANISMS
Thrombosis within the venous system results in
outflow obstruction, venous congestion, and
a consequent increase in capillary hydrostatic
pressure, driving fluid into the interstitium and
producing edema. A persistent increase in hydro-
static pressure may result in red blood cell diape-
desis, and if in excess of arterial pressure,
a reduction of arterial inflow and arterial ischemia
can occur.SPECTRUM OF BRAIN INJURY IN CSVT
The spectrum of brain injury in CSVT varies from
venous congestion, which may or may not be
appreciable on neuroimaging (Fig. 1), to the
more recognized parenchymal ischemic injury,
which may be cortical or subcortical, and involve
deep gray matter (see Fig. 1; Fig. 2). The majority
of the parenchymal infarcts are hemorrhagic. Less
well appreciated is CSVT-related primary
subarachnoid and subdural hemorrhage. In
preterm and term neonates there is also an asso-
ciation between intraventricular hemorrhage (IVH)
and CSVT.22 Several studies demonstrate that
CSVT is the most frequently recognized cause of
symptomatic IVH, and is associated with basalganglia and thalamic hemorrhage in term
neonates. Deep venous thrombosis can be
accompanied by hemorrhage into the ventricles
as a result of blockage and hypertension in the
deep venous drainage system.10,23 Presumed
perinatal ischemic stroke is a subgroup of peri-
natal stroke and encompasses imaging-confirmed
focal infarction, which may be venous or arterial,
presenting after the neonatal period. Perinatal
venous infarction (PVI) is one of these periventric-
ular infarction syndromes, and is an underrecog-
nized cause of congenital hemiplegia.24RISK FACTORS FOR CSVT DEVELOPMENT
As is the case in adults, CSVT in neonates, infants,
and children is often multifactorial in etiology, with
a predisposing comorbid condition or infirmity
identified in up to 95% of those affected (see
Table 1). These conditions include common child-
hood illnesses such as fever, infection, dehydra-
tion, and anemia, as well as acute and chronic
medical conditions such as congenital heart
disease, nephrotic syndrome, systemic lupus er-
ythematosus, and malignancy (Table 2). As well
as the maternal, there are neonatal risk factors
for sinovenous thrombosis in the perinatal period
(Table 3), which parallel those in older children.
In addition to these systemic risk factors, throm-
bosis can develop and propagate in response to
local venous stasis. A large number of children
have coincident local head and/or neck pathology,
including head trauma, central nervous system
tumors, or recent intracranial surgery. Historically,
CSVT was a well-recognized complication of otitis
media and mastoiditis, and while less attention has
been paid recently to this important risk factor, otitis
media or mastoiditis has been identified in 24% to
62% of all childhood CSVT case series and cohorts
published in the last decade.1,5,7,13,27,28 Indeed, in
terms of observed frequency, infection appears to
be the most common condition associated with
CSVT in children outside of the neonatal period.
Anemia is frequently observed in children with
CSVT, though mechanisms for its contribution to
thrombus development are incompletely under-
stood. Iron deficiency anemia and microcytosis
are most commonly described7,25,29–33 some-
times in association with thrombocytosis, but
only one study with parallel controls is currently
available.25 CSVT has also been reported in
chronic anemias, such as hemolytic anemia
and Evans syndrome,34 b-thalassemia major,35
and sickle cell disease.36–40 The diagnosis of
anemia may be obscured by relative hemocon-
centration (particularly if dehydration is also
present) and a falsely elevated ferritin in the
Fig. 1. Case synopsis. A previously healthy 8-year-old girl was admittedwith a 3-week history of, intermittent emesis
and a 4-day history of occipital headache, and photophobia. Examination revealed severe dehydration, mild hyper-
tension, and tachycardia. Extensive thrombosis of both deep and superficial cerebral sinovenous systems was diag-
nosed on head CT and anticoagulation therapy was initiated. Progressive encephalopathy developed on hospital
day 5, necessitating admission to the intensive care unit. Unexplained tachycardia (heart rate >200) developed on
hospital day 15 and Graves disease was ultimately diagnosed (thyrotropin <0.01 mIU/L and free T4 >77.2 pmol/L.)
The patient was then started on methimazole. Comprehensive prothrombotic testing uncovered a heterozygous
mutation in the Factor V Leidengene. She completed 6months of anticoagulationwith subcutaneous lowmolecular
weight heparin. Follow-up neurologic examination revealed mild left incoordination and bilateral kinetic tremor
(left > right), perhaps secondary to hemorrhagic venous infarction of the right thalamus. (A, B) Non-contrast axial
head CT done at admission revealed heterogeneous attenuation within the right transverse and sigmoid sinuses
(A) and posterior aspect of the superior sagittal sinus (B), suggesting acute and subacute components of the
thrombus. (C,D) Contrast CTreveals fillingdefectswithin these same sinuses. (E, F) Initial axial fluid-attenuated inver-
sion recovery (FLAIR) (E), T1 and T2 (not shown) MRI sequences as well as diffusion-weighted imaging (DWI) (F)
showed normal brain parenchyma. (H, I) A repeat MRI done in the subacute period after the patient’s clinical dete-
rioration showed increased signal within the thalami bilaterally on FLAIR (H) and T2 (not shown). Corresponding
areas of diffusion restriction on DWI (I) suggested venous congestion and infarction secondary to thalamostriate
venous occlusion. Peripheral blooming was seen in the right thalamus on gradient echo sequences (not shown),
evidence of petechial hemorrhage. (K, L) Follow-up MRI done 6 months after diagnosis showed low FLAIR (K) and
T2 signal (not shown) in the right thalamus, corresponding to hemosiderin deposits from hemorrhagic infarction.
DWI (L) similarly showed low signal. (G, J, M) Three-dimensional phase contrast MR venograms performed acutely
(G) and subacutely (J) showed extensive sinovenous thrombosis, involving the right transverse and sigmoid sinuses
(black arrow), right internal jugular vein, posterior superior and inferior sagittal sinuses, torcula, vein of Galen, basal
vein of Rosenthal, and internal cerebral and thalamostriate veins. Left parietal cortical veins were also thrombosed
(white arrowheads). The left transverse and sigmoid sinuses were spared (white arrow). Interval recanalization of
the left internal cerebral vein and basal vein of Rosenthal was seen subacutely (J). A 2-dimensional time-of-flight
MR venogram done 6 months post diagnosis (M) showed persistently absent flow within the right transverse sinus,
but partially visualized flowwithin the right sigmoid sinus and jugular bulb (black arrow), evidence of either partial
recanalization or slow flow within these sinuses. There was complete recanalization of the superior sagittal sinus,
deep venous system, and left parietal cortical veins.
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Fig. 1. (continued)
Cerebral Venous Sinus Thrombosis in Children 517acute setting, so it is important that the diag-
nosis of anemia and iron deficiency should be
comprehensively excluded or treated in all chil-
dren with CSVT.
Dehydration is another important treatable risk
factor for pediatric CSVT, secondary either to
increased fluid losses from nephrotic syndrome30
or gastroenteritis, or poor oral intake with infection
or systemic medical illness. Dehydration and hy-
povolemia should always be carefully assessedand corrected to prevent thrombus propagation
and promote recanalization of the affected vessel.
Other common illnesses, including meningitis41
and diabetes,29 may be complicated by CSVT,
which can be difficult to diagnose so that data
for incidence remain a minimum estimate.28
Although occasionally recognized, there are few
data on the prevalence of CSVT in convulsive and
nonconvulsive seizures and status epilepticus42
and otherwise unexplained hydrocephalus.43
Fig. 2. Spectrum of CSVTrelated brain injury. BG, basal
ganglia; SDH, subdural hemorrhage; IVH, intraventric-
ular hemorrhage; SAH, subarachnoid hemorrhage.
Dlamini et al518CSVT may also be an important determinant of
outcome in minor head injury,44,45 and in trau-
matic11,46,47 and nontraumatic coma (eg, secondary
to cerebral malaria).48 Other infections more
commonly seen in tropical countries (eg, neurocys-
tercercosis), may also be associated with CSVT.49
Certain chronic conditions such as inflammatory
bowel disease,50 systemic lupus erythematosus,51
Cushing syndrome,52 and thyrotoxicosis53 (see
Fig. 1) appear to predispose to CSVT, which may
present in unusual ways, including psychiatric
manifestations.54PROTHROMBOTIC DISORDERS THAT MAY BE
RISK FACTORS FOR CSVT IN CHILDREN
Prothrombotic stateshavebeen identified in 24%to
64%of children5,7,28,55,56 and in 20%of neonates10
with CSVT in recent series (see Table 1). However,
these data are difficult to interpret as (1) the number
and types of available prothrombotic tests have
varied over the past 2 decades and vary between
centers, (2) not all children have full prothrombotic
profiles assessed, and (3) results may depend on
the timing of testing. Indeed, acquired prothrom-
botic tendencies, such as protein C, protein S,
and/or antithrombin deficiency secondary to infec-
tion or protein loss (eg, in nephrotic syndrome),
may normalize on repeat investigation with resolu-
tion of the acute process. High factor VIII levels,
which may be determined by genetic and acquired
factors, are also common7,57 but there are currently
nocontrolleddata. Although there is evidence for an
excess of genetic polymorphisms, the relative
importance of the Factor V Leiden mutation is less
clear in children than in adults.5,56,58 While
uncommon, the prothrombin 20210 mutation does
appear to be a risk factor for recurrence and should
be excluded.4
Homocystinuria is a rarely described associa-
tion,59 and homozygotes for the thermolabile
variant of the methylene tetrahydrofolate reduc-
tase (MTHFR) gene may have an increased risk
of CSVT.60 Hyperhomocysteinemia (which hasbeen shown to be a risk factor in 2 case-controlled
series in adults61,62) and its genetic determinants
may be worth excluding or treating with folic acid
and vitamin B6 and B12 supplementation, as this
has few risks, but further studies will be important.
Apart from those with the prothrombin 20210
mutation, who should probably be anticoagulated
in high-risk situations,4 there are few data on
whether long-term treatment of any of the other
prothrombotic disorders reduces the recurrence
risk.5,28 Investigation for prothrombotic disorders
is expensive and may not guide management
except in certain circumstances, such as deter-
mining the risks of using oral contraception (see
later discussion). Nevertheless, full prothrombotic
profiles should be considered in all affected chil-
dren, to better counsel parents of patients and
also contribute data that may improve our under-
standing of mechanisms underlying CSVT
development.CLINICAL PRESENTATION
The clinical manifestations of CSVT are nonspe-
cific, and may be subtle in neonates and children
(Table 4). Although rare, cerebral sinovenous
thrombosis can occur antenatally as early as the
second trimester and is detectable by fetal real-
time and color Doppler ultrasound.63 Reported
cases are likely an underestimation of frequency,
as the imaging characteristics mimic those of an
intracranial tumor. Thrombosis often occurs within
the posterior fossa and may occur in association
with dural malformations such as dural arteriove-
nous shunts. Spontaneous regression of the
thrombosis may occur, with a favorable outcome.
Diagnosis is important, as therapeutic termina-
tions of pregnancy have resulted in misdiag-
nosis.64 The fetal venous drainage system may
be less susceptible to thrombosis compared with
the neonate, as fetal anastomoses may result in
the fetus being able to redirect venous blood
flow.65
Outside of the antenatal period most of the clin-
ical scenarios occur at all ages, and the clinician
requires a high index of suspicion to make the
diagnosis. The clinical manifestations of CSVT
are nonspecific, may be subtle (see Table 4),
and may overlap with predisposing conditions
such as infection and dehydration.7,12 Seizures,
altered levels of consciousness and encephalop-
athy, focal neurologic deficits (cranial nerve
palsies, hemiparesis, hemisensory loss), and
diffuse neurologic symptoms (headache, nausea,
emesis) may result. While most of the clinical
symptoms can occur at any age, seizures are
more common in neonates, and focal and diffuse
Table 2
Conditions associated with pediatric cerebral
sinovenous thrombosis
General
Dehydration
Infection
Fever
Hypoxic-ischemic injury
Post lumbar puncture
Head and neck infections
Otitis media and mastoiditis
Meningitis
Sinusitis
Upper respiratory tract infection
Other head and neck disorders
Head injury
Post intracranial surgery
Hydrocephalus (ventriculoperitoneal shunt)
Anemia
Iron deficiency
Sickle cell disease
Thalassemia
Autoimmune hemolytic anemia
Paroxysmal nocturnal hemoglobinuria
Autoimmune disorders
Behc¸et disease
Systemic lupus erythematosus
Antiphospholipid antibody syndrome
Inflammatory bowel disease (ulcerative
colitis, Crohn disease)
Thyrotoxicosis
Cushing syndrome
Idiopathic thrombocytopenic purpura
Malignancy
Leukemia
Lymphoma
Central nervous system tumors
Cardiac disease
Cyanotic congenital heart disease25,26
Post-operative
Postcatheterization
Renal disease
Nephrotic syndrome
Hemolytic-uremic syndrome
Drugs
L-Asparaginase
Oral contraceptives
Corticosteroids
Epoetin-a
Chromosomal disorders
Down syndrome
Metabolic conditions
Diabetic ketoacidosis
Homocystinuria
Table 3
Conditions associated with neonatal cerebral
sinovenous thrombosis
Maternal conditions
Chorioamnionitis
Diabetes
Hypertension
Perinatal conditions
Meconium aspiration
Apgar <7 at 5 min
Intubated at birth
Neonatal infection
Polycythemia
Severe dehydration
Pneumonia
ECMO treatment
Congenital heart disease
Disseminated intravascular coagulation
Congenital diaphragmatic hernia
Abbreviation: ECMO,extracorporealmembraneoxidation.
Cerebral Venous Sinus Thrombosis in Children 519neurologic signs are more common in older infants
and children.12 The clinician should consider this
diagnosis in a wide range of acute neurologic
presentations in childhood, including those
accompanied by neuroimaging evidence of hydro-
cephalus,43 subdural effusion or hematoma,66
subarachnoid hemorrhage,67 or intracerebral
hemorrhage or infarction, particularly in the pari-
etal or occipital regions.7 Presentation with pseu-
dotumor cerebri68 and isolated headache69 have
been well documented. A high index of suspicion
is necessary to effect earlier detection and thera-
peutic strategies.DIAGNOSIS
Neuroimaging Techniques
The keys to neuroradiological diagnosis (Table 5)
are (1) a high index of suspicion of the diagnosis
in the acute phase so that imaging is performed
early, as the venous sinuses may recanalize before
detection,4,7,70 and (2) a good working relationship
between treating clinicians and neuroradiologists
Table 4
Symptoms and signs of cerebral sinovenous
thrombosis in older children
Seizures (focal, generalized)
Depressed level of consciousness and coma
Lethargy
Nausea
Vomiting
Headache
Visual impairment (transient obscurations,
reduced acuity, blindness)
Papilledema
Hemiparesis
Hemisensory loss
Ataxia
Speech impairment, mutism
Cranial nerve palsies (VI)
Acute psychiatric symptoms
Respiratory failure (in neonates)
Jittery movements (in neonates)
Dlamini et al520so that definitive neuroimaging and investigations
are pursued if necessary.
Anatomic and clinical studies demonstrate a link
between venous drainage and location of paren-
chymal infarcts.71,72 Unenhanced computedTable 5
Diagnosis of sinovenous thrombosis
Level of Evidence
High index of suspicion in
children with associated
pre-existing disorder
IC
High index of suspicion in
children presenting with
headache, seizures, coma
IC
Plain CT IC
MRI (T1-, T2-weighted, T2*,
FLAIR)
IC
MRI with contrast IIC
Diffusion-weighted MRI IIC
CT venography IIC
MR venography IIC
Contrast MR venography IIC
Transcranial Doppler IIC
Conventional digital
subtraction angiography
IIC
Abbreviations: CT, computed tomography; FLAIR, fluid-
attenuated inversion recovery; MR, magnetic resonance;
MRI, magnetic resonance imaging.tomography (CT) scans may detect deep venous
thrombosis as linear densities in the expected loca-
tions of the deep and cortical veins (see Fig. 1A,
B).11,73 As the thrombus becomes less dense,
contrast may demonstrate the ‘‘empty delta’’
sign, a filling defect, in the posterior part of the
sagittal sinus (see Fig. 1C, D).11,28 However, CT
scan with contrast misses the diagnosis of CSVT
in up to 40% of patients.9,27,28 Diffusion and perfu-
sion magnetic resonance imaging (MRI) may play
a role in detecting venous congestion in cerebral
venous thrombosis (see Fig. 1H, I) and in the differ-
entiation of cytotoxic and vasogenic edema, but
does not differentiate venous from arterial infarc-
tion. CT venography or MRI with venography
(MRV) are now themethods of choice for investiga-
tion of CSVT.7,9,71,74 The diagnosis is established
bydemonstrating a lack of flow in the cerebral veins
(see Fig. 1G,J,M) with or without typical images of
brain infarction (see Fig. 1E, F, H, I).
The superficial venous system is more
frequently involved than the deep system, and
the most common sites of CSVT are the trans-
verse, superior sagittal, sigmoid, and straight
sinuses. Between one- and two-thirds of children
with CSVT may have parenchymal brain lesions
such as venous infarction and hemorrhage.71
MRI and MRV are important in both the demon-
stration of the infarct and the clot within the
vessels.71 On MRI, the thrombus is readily recog-
nizable in the subacute phase, when it is of high
signal on a T1-weighted scan, and MRV may not
be required. In the acute phase, the thrombus is
isodense with brain on T1-weighted imaging and
of low signal on T2-weighted imaging. This
appearance can be mistaken for flowing blood,
but MRV will demonstrate an absence of flow in
the thrombosed sinus. T2*-weighted MRI seems
to be more sensitive than T1- or T2-weighted or
fluid-attenuated inversion recovery (FLAIR)
imaging in demonstrating venous thrombosis and
associated hemorrhage.75,76 However, MRI and
MRV are techniques prone to flow artifacts (see
Fig. 1M) and in equivocal cases, particularly if
deep venous infarction or cortical venous throm-
bosis is suspected, an endoluminal technique
such as high-resolution CT venography or conven-
tional digital subtraction angiography may be
required as a final arbiter.INVESTIGATION, MONITORING,
AND MANAGEMENT
Laboratory investigation of adult and pediatric
CSVT is similar (Table 6). Treatment of CSVT
(Table 7) has historically involved general
supportive care or symptomatic measures, such
Table 6
Laboratory investigations in cryptogenic
cerebral venous sinus thrombosis
Level of Evidence
Essential
Blood culture IC
Full blood count IC
Iron studies IC
Thyroid function IC
Antinuclear antibody
or DNA binding
IC
Potentially useful
Homocysteine IIB
Vitamin status, ie,
folate, B6, B12
IIB
Full prothrombotic
screen (DNA and
citrated samples)
IIB
Cerebral Venous Sinus Thrombosis in Children 521as correction of dehydration and hypovolemia,
antibiotics for cases involving infection, control of
seizures with anticonvulsants, and medical and
surgical measures aimed at decreasing intracranial
pressure. In cases of otitis media-related and
mastoiditis-related CSVT, many children receiveTable 7
Acute management
Level of
Evidence
Supportive treatment
Rehydration IC
Treat infection, eg, antibiotics
for meningitis/mastoiditis/
pharyngitis
IC
Treat cause, eg, mastoidectomy,
steroids for SLE, inflammatory
bowel
IC
Treat seizures IC
Treat iron deficiency IIB
Anticoagulate/monitor for 4 months whether or
not there is hemorrhage
IV heparin/APTT IIB
SC heparin/Factor Xa IIC
Warfarin/INR IIC
Thrombolysis IIC
Thrombectomy IIC
Surgical decompression IIC
Abbreviation: INR, international normalized ratio.parenteral antibiotic therapy, with either second-
or third-generation cephalosporins (Table 8). Anti-
biotic choice and treatment duration in children
with head and neck infections should be discussed
with a local infectious disease specialist and
consideration given to coverage with metronida-
zole, clindamycin, or vancomycin when anaerobic
organisms are implicated (ie, Fusobacterium nec-
rophorum in Lemierre syndrome or jugular venous
thrombophlebitis).42 The role of surgery, such as
mastoidectomy, myringotomy, and/or tympanos-
tomy tube insertion, in otitis media-related and
mastoiditis-related CSVT is unclear,77 but is often
performed based on the preference of the treating
otolaryngologist. Some patients develop intracra-
nial hypertensionwithin the clinical spectrumprevi-
ously described as ‘‘pseudotumor cerebri’’ or
‘‘otitic’’ communicating hydrocephalus, and may
require long-term acetazolamide therapy, serial
lumbar punctures, or lumboperitoneal shunting
(see section on Follow-up).
Pediatric case series published in the last decade
differ in their reported use of antithrombotic agents
after the diagnosis of CSVT is established. Treat-
ment regimensvarybetweencenters,butmanyold-
er infants andchildren receive anticoagulation in the
acute setting with either parenteral unfractionated
heparin, subcutaneous low molecular weight
heparin (LMWH), or oral warfarin (Coumadin; Bristol
Myers-Squibb) (see Table 1). Some centers prefer
to use unfractionated heparin acutely, as the effects
of heparin can be reversed if intracranialTable 8
Monitoring of child with acute sinovenous
thrombosis
Level of
Evidence
Clinical seizures (duration,
semiology)
IC
Level of consciousness (Glasgow
Coma Scale adapted for children)
IC
Focal neurologic signs, eg,
hemiparesis
IC
Visual acuity and fields IC
For those on intravenous heparin,
4-hourly APTT
IC
For those on subcutaneous heparin,
daily factor Xa
IC
For those who are unconscious and/
or ventilated:
Continuous EEG monitoring IIC
Intracranial pressure monitoring IIC
Repeat neuroimaging IIC
Dlamini et al522hemorrhage occurs. This regimen is often followed
by chronic anticoagulation with LMWH or Couma-
din for 3 to 6 months. Anticoagulation should be
carefully monitored, with activated partial thrombo-
plastin time (APTT) for unfractionated heparin, anti-
Xa for LMWH, or international normalized ratio for
Coumadin, to achieve adequate levels for efficacy
while preventing overdosage. However, anticoagu-
lationmay be terminated sooner than this if recana-
lization of the affected vessel(s) is demonstrated on
follow-up neuroimagingwithMRorCT venography.
At some centers, there seems to be a reluctance to
treat neonates with anticoagulation12,13,78 due to
perceived risks of worsening preexisting intracra-
nial hemorrhage or causing hemorrhagic transfor-
mation of bland venous infarction, coupled with
a lack of evidence demonstrating improved
outcome in neonates treated with anticoagulation.
However, treatment of neonates with LMWH
appears to be safe, and should at least be consid-
ered.79 Very few centers have reported on the use
of antiplatelet agents such as acetylsalicylic acid
(ASA)7,12 or dipyridamole in the acute or chronic1
settings.
There are currently no well-designed clinical
trials in children to support acute or chronic antith-
rombotic therapy with anticoagulants or antiplate-
let agents once the diagnosis of CSVT is made.
The only randomized placebo-controlled trial of
intravenous heparin in adults80 was stopped early
because there was clear evidence of benefit,
particularly in terms of mortality. Subsequent to
this, a randomized placebo-controlled trial of
subcutaneous LMWH in adults81 showed a trend
for better outcome in the treated group, but
the mortality was lower in this series and there
were more patients with milder presentations in
the placebo arm. Despite these limited data,
a recent Cochrane review concluded that anticoa-
gulation was safe, and there was some evidence
for a clinically important benefit.82
Single-center and small multicenter series in chil-
dren7,57,74,83 have shown that intravenous and
subcutaneousLMWHcanbeusedsafely inchildren,
with close monitoring of heparin levels or anti-Xa
levels when LMWH is employed (see Table 8). De-
Veber and colleagues84 initiated a prospective
cohort study of anticoagulant therapy in 30 children
with CSVT from 1992 to 1996, and reported
a mortality rate of 3 out of 8 untreated compared
with 0 of 22 treated children. One series suggested
that cognitive outcomemightbebetter in the antico-
agulated group,7 and pooled data from the Euro-
pean collaborative group found a reduced risk of
recurrence in those who were anticoagulated.4 In
adult series, patients with hemorrhage were antico-
agulated, and available evidence suggests that thebenefit of anticoagulation on improved outcome
outweighs the risk of new bleeding or extension of
old hemorrhage. There is currently a consensus
that in children beyond the neonatal period without
hemorrhage, anticoagulation should be consid-
ered.85–87
There are no randomized data on thromboly-
sis,1,3,88–90 thrombectomy,91 or surgical decom-
pression92,93 in CSVT even in adults,94 but each
has been used with apparent success in isolated
cases or small series of seriously ill patients,
including children, usually in coma and with
extensive thrombosis of superficial and deep
venous structures.79,88–90 A nonrandomized study
comparing urokinase thrombolysis with heparin in
adults suggested better functional outcome for
the thrombolysed patients but higher risk of hemor-
rhage.95 These patients have a high risk of
secondary complications, including status epilepti-
cus, hydrocephalus,95 and raised intracranial pres-
sure,96,97 and may benefit from intensive care and
monitoring of electroencephalograph and intracra-
nial pressure as well as neuroimaging (see Table 8).
MORTALITY AND MORBIDITY
CSVT-specific mortality is less than 10%, but
neurologic deficits are present at time of
discharge or follow-up examination in 17% to
79% of survivors, and motor and cognitive
sequelae may require long-term rehabilitative
regimens.1,7,28,98–100 Coma is a predictor of
death in childhood CSVT.7 Most published pedi-
atric cohorts have followed affected children for
relatively short periods, typically less than 2
years from time of diagnosis. Despite aggressive
therapy with antithrombotic agents, antibiotics,
and surgery in some cases, many children with
CSVT suffer chronic neurologic symptoms,
such as headache, visual impairment, and
cranial nerve VI palsy related to increased intra-
cranial pressure. Others display deficits related
to venous infarction ranging from developmental
delays and learning disabilities to hemiparesis
and hemisensory loss. In the series by Se´bire
and colleagues of children who presented at
more than 1 month of age,7 older age, lack of
parenchymal abnormality, anticoagulation, and
lateral and/or sigmoid sinus involvement were
independent predictors of good cognitive
outcome, although the last predicted pseudotu-
mor cerebri. More than 50% of neonates have
a poor outcome, and mortality is high.3,12
FOLLOW-UP
All children with CSVT require close monitoring for
neurologic and ophthalmologic symptoms and
Table 9
Management of risk factors to prevent
recurrence
Level of
Evidence
Improve diet, eg, 5 portions of
fruit and/or vegetables per day
IC
Reduce cow’s milk intake and
increase solids in infants and
toddlers
IC
Treat cause, eg, steroids for SLE,
IBD
IC
Suggest alternative
contraception
IB
Treat iron deficiency IIC
Treat hyperhomocysteinemia/
frank vitamin deficiency, eg,
folate, B6, or B12
IIC
Consider acute anticoagulation in
high-risk settings
IIA
Consider prolonged oral
anticoagulation after
recurrence
IIC
Cerebral Venous Sinus Thrombosis in Children 523signs related to increased intracranial pressure
and optic nerve compression. As visual impair-
ment and failure may go undetected by parents,
particularly in nonverbal children, ophthalmology
follow-up is warranted in the first year after diag-
nosis. Persistent headache, nausea, or vomiting
(particularly if nocturnal or early morning) mandate
repeat neuroimaging to exclude hydrocephalus,
CSVT propagation, and/or recurrence. Chronically
elevated intracranial pressure may respond to
treatment with steroids or acetazolamide, or may
require lumboperitoneal shunting.94,101,102 Occa-
sionally patients with cryptogenic CSVT later
manifest symptoms of an underlying disease (see
Fig. 1), such as systemic lupus erythematosus or
Behc¸et disease,103 so patients should be encour-
aged to report back if they have any other medical
concerns after diagnosis.
Follow-up neuroimaging with MR or CT venog-
raphy should be undertaken in the acute phase
and during the first year of follow-up to look for
evidence of extension or persistence or recanali-
zation of venous occlusion, or the development
of venous stenosis. Some centers perform this at
3, 6, and 12 months after diagnosis. In the Euro-
pean study, complete and partial recanalization
occurred in 46% and 42%, respectively.4PREDICTION AND PREVENTION
OF RECURRENCE
Between 10% and 20% of children who have
a cerebral venous sinus thrombosis will experi-
ence a recurrent symptomatic venous event, at
least half of which are systemic rather than cere-
bral (Table 9).4,5,7,28 In a multicenter European
study,4 recurrent venous thrombosis only
occurred in children whose first CSVT was diag-
nosed after age 2 years; the underlying medical
condition had no effect. In Cox regression anal-
yses, nonadministration of anticoagulant before
relapse (hazard ratio [HR] 11.2, 95% confidence
interval [CI] 3.4–37.0; P<.0001), persistent occlu-
sion on repeat venous imaging (HR 4.1, 95% CI
1.1–14.8; P 5 .032), and heterozygosity for the
G20210A mutation in factor II (HR 4.3, 95% CI
1.1–16.2; P 5 .034) were independently associ-
ated with recurrence. Among patients who had
recurrent CSVT, 70% (15) occurred within 6
months after the initial episode.
There have been no trials of strategies to prevent
recurrent cerebral or systemic venous thrombosis
in children, but these cohort data suggest that anti-
coagulation should be considered for up to 6
months after the first episode. It would be difficult
to recommend a higher risk strategy, such as pro-
longed oral anticoagulation, unless recurrencehad already occurred, but there is a case for antico-
agulation in acute settings where the risk of recur-
rence is likely to be high, for example, relapse of
nephrotic syndrome or active inflammatory bowel
disease.4 There is also a little evidence that stop-
ping the use of oral contraceptives reduces the
risk, and there are several low-risk strategies,
such as improving the quality of the diet, which
can be recommended (see Table 9).SUMMARY
Cerebral sinovenous thrombosis is an underdiag-
nosed but important cause of stroke in childhood
occurring most often in the neonatal period.
Mortality and morbidity are significant. However,
there are several unanswered questions regarding
CSVT, particularly in relation to diagnosis in children
presenting with hydrocephalus, or in coma or status
epilepticus in the context of common conditions
suchashead injury, aswell as the safety andefficacy
of treatment in this age group. Hence the need for
further high quality studies and where possible -
well conducted randomized controlled trials.REFERENCES
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